"King of Pharma" Delivers Stellar Q1 Report, Goldman Sachs Comments on WuXi AppTec: Full-Year Performance Still Has Upside Potential
"King of Pharma" Delivers Stellar Q1 Report; Goldman Sachs Comments on WuXi AppTec: Full-Year Performance Still Has Room to Grow
#Innovative Drugs #WuXi AppTec$WUXI APPTEC(02359.HK) $WuXi AppTec(603259.SH)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments